Enveric Biosciences Inc. (NASDAQ: ENVB)
$0.53
-0.0051 ( -0.94% ) 454.3K
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders. The company's lead program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. Enveric is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, being studied as a treatment of psychiatric disorders.
Market Data
Open
$0.53
Previous close
$0.54
Volume
454.3K
Market cap
$4.25M
Day range
$0.48 - $0.54
52 week range
$0.41 - $3.90
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
8-k | 8K-related | 15 | Jul 15, 2024 |
3 | Insider transactions | 1 | Jun 03, 2024 |
8-k | 8K-related | 13 | May 29, 2024 |
8-k | 8K-related | 13 | May 23, 2024 |
8-k | 8K-related | 13 | May 17, 2024 |
8-k | 8K-related | 15 | May 15, 2024 |
10-q | Quarterly Reports | 59 | May 15, 2024 |
8-k | 8K-related | 19 | May 03, 2024 |
def | Proxies and info statements | 5 | Apr 16, 2024 |
ars | Annual reports | 1 | Apr 16, 2024 |